A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02282527 |
Recruitment Status :
Completed
First Posted : November 4, 2014
Results First Posted : March 13, 2017
Last Update Posted : March 13, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alpha₁-Antitrypsin Deficiency | Biological: Liquid Alpha₁-PI Biological: Prolastin-C | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha₁-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha₁-Antitrypsin Deficiency |
Study Start Date : | October 2014 |
Actual Primary Completion Date : | January 2016 |
Actual Study Completion Date : | January 2016 |

Arm | Intervention/treatment |
---|---|
Treatment Sequence 1
Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
|
Biological: Liquid Alpha₁-PI
Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions Biological: Prolastin-C Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions |
Treatment Sequence 2
Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
|
Biological: Liquid Alpha₁-PI
Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions Biological: Prolastin-C Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions |
- AUC(0-7 Days) Based on Antigenic Content [ Time Frame: pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose ]The primary PK objective of this study was to demonstrate the bioequivalence of Liquid Alpha₁-PI 60 mg/kg to Prolastin-C 60 mg/kg, as measured by AUC from 0 to 7 days (AUC0-7days) using an antigenic content assay of alpha₁-PI, at approximate steady state in subjects with AATD.
- AUC(0-7 Days) Based on Functional Activity [ Time Frame: pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose ]The exploratory PK objective of this study was to demonstrate the bioequivalence of Liquid Alpha₁-PI 60 mg/kg to Prolastin-C 60 mg/kg, as measured by AUC from 0 to 7 days (AUC 0-7 days) using a functional activity assay of alpha₁-PI, at approximate steady state in subjects with AATD.
- Number of Subjects With Immunogenicity Response [ Time Frame: Weeks 1, 9, 17, and 20 ]Blood samples for immunogenicity testing were collected at Weeks 1 (Baseline), 9, 17, and 20. Any samples that tested positive for alpha₁-PI antibodies were tested for neutralizing antibodies and antibody titer. Immunogenicity testing was performed using validated assays in a multitiered approach. Samples collected at Week 1 (Baseline) and at Weeks 9 and 20 were tested for immunogenicity while samples collected at Week 17 were to be tested for immunogenicity only if deemed appropriate (eg, unexpected PK profile).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Be between 18 and 70 years of age, inclusive
- Had a diagnosis of congenital AATD
- Had a documented total alpha₁-PI level < 11 µM. If the total alpha₁-PI level had yet to be documented, a blood draw for total alpha₁-PI level was obtained at the Screening Visit
- Had a post-bronchodilator Forced expiratory volume in 1 second (FEV1) ≥ 30% and < 80% of predicted and FEV1/forced vital capacity (FVC) < 70%
- If the subject had received alpha₁-PI augmentation therapy of any kind, he/she must have been be willing to discontinue that treatment at the Week 1 (Baseline) Visit and remain off any kind of alpha₁-PI treatment, other than the investigational products for this study, while participating in the study
Exclusion Criteria:
- Subject had a moderate or severe pulmonary exacerbation during the 4 weeks before the Week 1 (Baseline) Visit
- History of lung or liver transplant
- Any lung surgery during the past 2 years (excluding lung biopsy)
- Liver cirrhosis confirmed by biopsy
- Elevated liver enzymes (aspartate transaminase [AST], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]) equal to or greater than 2.5 times the upper limit of normal
- Severe concomitant disease (e.g., congestive heart failure, clinically significant pulmonary fibrosis, malignant disease [with the exception of skin cancers other than melanoma], history of acute hypersensitivity pneumonitis reaction, or current chronic hypersensitivity pneumonitis)
- Females who were pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or abstinence) throughout the study
- Known previous infection with or clinical signs and symptoms consistent with current hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection
- Smoking during the past 6 months or a positive urine cotinine test at the Screening Visit that is due to smoking
- Participation in another investigational drug study within one month prior to the Week 1 (Baseline) Visit
- History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s)
- Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e.,10 mg every 2 days) within the 4 weeks prior to the Week 1 (Baseline) Visit inhaled steroids are not considered systemic steroids)
- Use of systemic or aerosolized antibiotics for an exacerbation within the 4 weeks prior to the Week 1 (Baseline) Visit
- Known selective or severe Immunoglobulin A (IgA) deficiency

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02282527
United States, Colorado | |
National Jewish Health | |
Denver, Colorado, United States, 80206 | |
United States, Florida | |
University of Florida Gainesville | |
Gainesville, Florida, United States, 32610 | |
University of Miami - Miller School of Medicine | |
Miami, Florida, United States, 33136 | |
United States, North Carolina | |
PMG Research of Wilmington | |
Wilmington, North Carolina, United States, 28401 | |
United States, Oregon | |
Oregon Health and Science University | |
Portland, Oregon, United States, 97239 | |
United States, Texas | |
University of Texas Health Science Center | |
Tyler, Texas, United States, 75708 |
Responsible Party: | Grifols Therapeutics LLC |
ClinicalTrials.gov Identifier: | NCT02282527 |
Other Study ID Numbers: |
GTI1402 |
First Posted: | November 4, 2014 Key Record Dates |
Results First Posted: | March 13, 2017 |
Last Update Posted: | March 13, 2017 |
Last Verified: | January 2017 |
Alpha 1-Antitrypsin Deficiency Liver Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Subcutaneous Emphysema Emphysema |
Pathologic Processes Alpha 1-Antitrypsin Trypsin Inhibitors Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |